MA27075A1 - Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline - Google Patents
Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazolineInfo
- Publication number
- MA27075A1 MA27075A1 MA27623A MA27623A MA27075A1 MA 27075 A1 MA27075 A1 MA 27075A1 MA 27623 A MA27623 A MA 27623A MA 27623 A MA27623 A MA 27623A MA 27075 A1 MA27075 A1 MA 27075A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydroisoquinol
- quinazoline
- dimethoxy
- pyridyl
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 11 Octobre 2001 0124455.7 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulations pharmaceutiques pour la libération contrôlée de la 4-amino-6,7-diméthoxy-2-(5-méthanesulfonamido-1,2,3, 4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline La présente invention propose une formulation pharmaceutique à libération contrôlée pour administration orale, comprenant de la 4-amino-6,7-diméthoxy-2-(5-méthanesulfonamido-1,2,3,4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, ou un de ses sels pharmaceutiquement acceptables, et un adjuvant, diluant ou support pharmaceutiquement acceptable, ladite formulation étant caractérisée en ce qu'elle est adaptée a libérer au moins 50 % en poids de la 4-amino-6,7-diméthoxy-2-(5-méthane-sulfonamido-1,2,3,4-tétrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, ou de son sel pharmaceutiquement acceptable, au bout de 6 heures dans l'Appareil 1 décrit dans la Pharmacopée des Etats-Unis d'Amérique 24 (2000), pages 1941-1943, comprenant des récipients de 1 litre, des paniers à mailles no. 40 (ouvertures de 0,4 mm), à une vitesse de rotation de 100 tr/min, et avec un milieu de dissolution consistant en 900 ml d'acide chlorhydrique 0,01 M contenant 0,7 % en poids / volume de chlorure de sodium à 37o.C. Les formulations conformes à la présente invention conviennent au traitement de l'hyperplasie prostatique bénigne (HPB).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124455.7A GB0124455D0 (en) | 2001-10-11 | 2001-10-11 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27075A1 true MA27075A1 (fr) | 2004-12-20 |
Family
ID=9923660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27623A MA27075A1 (fr) | 2001-10-11 | 2004-04-08 | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1434570B8 (fr) |
| JP (1) | JP4131471B2 (fr) |
| KR (1) | KR20050032510A (fr) |
| CN (1) | CN1568180A (fr) |
| AP (1) | AP2004003001A0 (fr) |
| AR (1) | AR036782A1 (fr) |
| AT (1) | ATE303135T1 (fr) |
| BR (1) | BR0213196A (fr) |
| CA (1) | CA2461168A1 (fr) |
| CO (1) | CO5560534A2 (fr) |
| DE (1) | DE60205925T2 (fr) |
| DK (1) | DK1434570T3 (fr) |
| DO (1) | DOP2002000464A (fr) |
| EA (1) | EA006168B1 (fr) |
| ES (1) | ES2246017T3 (fr) |
| GB (1) | GB0124455D0 (fr) |
| GT (1) | GT200200184A (fr) |
| HR (1) | HRP20040261A2 (fr) |
| HU (1) | HUP0600064A3 (fr) |
| IL (1) | IL160969A0 (fr) |
| IS (1) | IS7179A (fr) |
| MA (1) | MA27075A1 (fr) |
| MX (1) | MXPA04003293A (fr) |
| NO (1) | NO20041520L (fr) |
| OA (1) | OA12709A (fr) |
| PA (1) | PA8556001A1 (fr) |
| PE (1) | PE20030551A1 (fr) |
| PL (1) | PL369666A1 (fr) |
| SV (1) | SV2004001279A (fr) |
| UY (1) | UY27477A1 (fr) |
| WO (1) | WO2003032956A1 (fr) |
| ZA (1) | ZA200401976B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| AP2015008789A0 (en) | 2013-03-14 | 2015-10-31 | Cytokinetics Inc | Heterocyclic compounds and their uses |
| KR101943592B1 (ko) | 2017-08-31 | 2019-01-30 | 조현우 | 데이터 마이닝 기법을 이용한 전자가계부 시스템 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0466986B1 (fr) * | 1990-07-02 | 1994-04-27 | Bend Research, Inc. | Perles asymétriques et microporeuses à libération contrôlée |
| FR2752737B1 (fr) * | 1996-08-29 | 1998-10-02 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| GEP20043364B (en) * | 2000-03-03 | 2004-03-10 | Pfizer | 4-Amino-6,7-Dimethoxy-2-(5-Methanesulfonamido-1,2,3,4- Tetrahydroisoquinol-2-Yl)-5-(2-Pyridyl) Quinazoline Mesylat And Polymorphs |
-
2001
- 2001-10-11 GB GBGB0124455.7A patent/GB0124455D0/en not_active Ceased
-
2002
- 2002-09-12 DO DO2002000464A patent/DOP2002000464A/es unknown
- 2002-09-17 GT GT200200184A patent/GT200200184A/es unknown
- 2002-09-30 HU HU0600064A patent/HUP0600064A3/hu unknown
- 2002-09-30 JP JP2003535760A patent/JP4131471B2/ja not_active Expired - Fee Related
- 2002-09-30 AT AT02775048T patent/ATE303135T1/de not_active IP Right Cessation
- 2002-09-30 CA CA002461168A patent/CA2461168A1/fr not_active Abandoned
- 2002-09-30 OA OA1200400094A patent/OA12709A/en unknown
- 2002-09-30 EA EA200400431A patent/EA006168B1/ru not_active IP Right Cessation
- 2002-09-30 AP APAP/P/2004/003001A patent/AP2004003001A0/en unknown
- 2002-09-30 CN CNA02820042XA patent/CN1568180A/zh active Pending
- 2002-09-30 KR KR1020047005316A patent/KR20050032510A/ko not_active Application Discontinuation
- 2002-09-30 PL PL02369666A patent/PL369666A1/xx not_active Application Discontinuation
- 2002-09-30 BR BR0213196-0A patent/BR0213196A/pt not_active IP Right Cessation
- 2002-09-30 WO PCT/IB2002/004040 patent/WO2003032956A1/fr active IP Right Grant
- 2002-09-30 ES ES02775048T patent/ES2246017T3/es not_active Expired - Lifetime
- 2002-09-30 DE DE60205925T patent/DE60205925T2/de not_active Expired - Lifetime
- 2002-09-30 DK DK02775048T patent/DK1434570T3/da active
- 2002-09-30 EP EP02775048A patent/EP1434570B8/fr not_active Expired - Lifetime
- 2002-09-30 MX MXPA04003293A patent/MXPA04003293A/es active IP Right Grant
- 2002-09-30 IL IL16096902A patent/IL160969A0/xx unknown
- 2002-10-09 UY UY27477A patent/UY27477A1/es not_active Application Discontinuation
- 2002-10-09 AR ARP020103805A patent/AR036782A1/es unknown
- 2002-10-09 PE PE2002000996A patent/PE20030551A1/es not_active Application Discontinuation
- 2002-10-10 SV SV2002001279A patent/SV2004001279A/es not_active Application Discontinuation
- 2002-10-10 PA PA20028556001A patent/PA8556001A1/es unknown
-
2004
- 2004-03-11 IS IS7179A patent/IS7179A/is unknown
- 2004-03-11 ZA ZA200401976A patent/ZA200401976B/en unknown
- 2004-03-17 HR HR20040261A patent/HRP20040261A2/hr not_active Application Discontinuation
- 2004-03-18 CO CO04025929A patent/CO5560534A2/es not_active Application Discontinuation
- 2004-04-05 NO NO20041520A patent/NO20041520L/no unknown
- 2004-04-08 MA MA27623A patent/MA27075A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27153A1 (fr) | Formulations pharmaceutiques de derives de platine | |
| MA26700A1 (fr) | FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. | |
| CA2282082A1 (fr) | Microgranules contenant du cisplatine | |
| TNSN00232A1 (fr) | Derives de 2,4-diaminopyrimidine nouveaux, et compositions les contenant | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| AU3913297A (en) | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug | |
| BE899635A (fr) | Compositions pharmaceutiques. | |
| MA27442A1 (fr) | Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| BE900660A (fr) | Composition therapeutique pour le traitement des sequelles d'intoxication. | |
| MA27054A1 (fr) | Formulation de suspension orale stabilisee | |
| TNSN94099A1 (fr) | Nouvelles compositions d'emulsions | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| MA27980A1 (fr) | Nouvelle composition | |
| JP2010540442A (ja) | キノロンを含む組成物及び感染症を治療し又は制御するための方法 | |
| MA27021A1 (fr) | Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant | |
| MA27075A1 (fr) | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline | |
| CA2503211A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
| Chiang et al. | Asymptomatic hypertension in the ED | |
| JP2002193839A (ja) | ココア製剤 | |
| EP1103253A3 (fr) | Agent filmogène aqueux de revêtement et préparation solide à utilisation orale | |
| TNSN04054A1 (fr) | Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline | |
| MA28224A1 (fr) | Nitro-oxyderives de medicaments contre l'hypertension. | |
| JP2011111418A (ja) | 口腔内局所投与に適したウイルス感染予防製剤 | |
| MA26876A1 (fr) | Mesylate et formes polymorphes de 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-isoquinol-2-yl)-5-(2-pyridyl)quinazoline |